PN-943 in Adults With Moderate to Severe Active Ulcerative Colitis (UC)

Summary

The purpose of the study is to evaluate the safety, tolerability, and clinical efficacy of PN-943 450 mg twice daily \[BID\] and PN-943 150 mg BID, compared with placebo BID, in subjects with moderate to severe active Ulcerative Colitis (UC).

Timeline

Start

2020-08-05

Primary completion

2023-02-16

Completion

2023-02-16

Drugs

Indications